Nurix Therapeutics Inc (NASDAQ:NRIX) saw its stock jump 10% on Wednesday after announcing the start of its pivotal DAYBreak clinical trial — a single-arm Phase 2 study evaluating bexobrutideg in patients with relapsed or refractory chronic lymphocytic leukemia (CLL).
The biopharmaceutical company, which specializes in targeted protein degradation therapies, will test a once-daily 600 mg dose in the trial. This dosage was selected based on results from a randomized Phase 1b cohort and in alignment with global regulators, including the U.S. Food and Drug Administration (FDA), Medicines and Healthcare products Regulatory Agency (MHRA), and European Medicines Agency (EMA).
“The initiation of the DAYBreak study marks Nurix’s transition to a pivotal-stage company and a major milestone for bexobrutideg, which our data demonstrate has a potential best-in-class profile,” said Arthur T. Sands, M.D., Ph.D., president and CEO of Nurix.
The DAYBreak trial will enroll CLL patients whose disease has progressed after multiple treatments. It aims to generate data that could support an Accelerated Approval submission, addressing a critical unmet need in this patient group.
Nurix also plans to begin a global, randomized Phase 3 trial in the first half of 2026, targeting CLL patients whose disease has advanced despite treatment with covalent BTK inhibitors. That study will compare bexobrutideg monotherapy with the investigator’s choice of alternative therapies.
The company will provide further updates on the program and present new preclinical findings during an investor webcast today, highlighting the drug’s potential best-in-class BTK degrader profile.